Stereotaxis Reports Fourth Quarter and Full Year 2007 Financi...(eter we believe that theapproximately 25...)

Date:3/3/2008

eter, we believe that the approximately 250 cases performed to date in Europe and Canada with this catheter, have established a new standard for the safe efficacious treatment of complex arrhythmias and we can build on this, as well as on our successful new Odyssey platform and new offerings in the vascular arena, to achieve continued strong growth in our business," Mr. Hogg concluded

Fourth Quarter Financial Performance

Gross profit totaled $6.5 million in the fourth quarter of 2007, or 63.7% of revenue. This compares with gross profit of $8.2 million, or 58.6% of revenue in the fourth quarter of 2006. The improvement in the gross profit margin in 2007 reflected a 5% increase in average selling price for the Niobe system. Gross profit margin for the year 2007 approached 66% exclusive of the inventory impairment charge recorded in the second quarter.

Total operating expenses increased 28% to $18.8 million in the quarter, compared with $14.7 million in the fourth quarter of 2006. The increase was driven by higher sales and marketing expense, as well as increased research and development related to expenses for new product introductions and further device development. The Company reported a net loss for the fourth quarter of 2007 of $12.2 million, or $0.34 per share. This compares to a net loss of $6.2 million, or $0.18 per share, in the fourth quarter of 2006. The weighted average shares for the recent fourth quarter were 36.3 million compared with 34.0 million in the fourth quarter of last year. The increase in weighted average shares reflected the issuance of 1.9 million shares in a sale of common stock in a registered direct offering completed in March 2007 pursuant to a shelf registration as well as the exercise of warrants in late 2006.

For the full year 2007, the Company reported a net loss of $48.1 million versus a net loss of $45.7 million for 2006. On a per share basis, the net loss in 2007 was $1.34 compared with $1.39 in 2006. <
'/>"/>

SOURCE Stereotaxis, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer
2. Stereotaxis Announces FDA Approval of Its Partnered Magnetic Irrigated Catheter
3. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
4. Genetic Engineering & Biotechnology News reports on advances in miRNA
5. Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
6. Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
7. Cepheid Reports Fourth Quarter and Full Year 2007 Results
8. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
9. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
10. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
11. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results